Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

EstoniaBack to Estonia

Clinical trials in Pohja-Tallinna Linnaosa – page 2

23 clinical trials in Pohja-Tallinna Linnaosa, Estonia. Every trial is listed in the EU Clinical Trials Register and updated daily.

EstoniaOur site in EstoniaKliinilisedUuringud.ee(opens in a new tab)
Pohja-Tallinna Linnaosa at a glance
23
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

23 trials in Pohja-Tallinna Linnaosa

Open in trial search

Urinary tract infection+1

Not recruiting

Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Aztreonam
  • Sponsor:Meiji Seika Pharma Co. Ltd.

Colitis ulcerative

Not recruiting

Study on Long-Term Safety of Etrasimod Arginine for Patients with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:EstoniaEstonia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Etrasimod Arginine
  • Sponsor:Arena Pharmaceuticals Inc.

Focal segmental glomerulosclerosis

Not recruiting

Study on the Effects of Sparsentan and Irbesartan for Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Irbesartan
  • Sponsor:Travere Therapeutics Inc.

Urinary tract infection

Not recruiting

Title: Comparison of oral tebipenem pivoxil versus intravenous imipenem-cilastatin in adults with complicated urinary tract infection or acute pyelonephritis

Registered drug
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Cilastatin
  • Sponsor:Spero Therapeutics Inc.

Study on the Effectiveness and Safety of Guselkumab and Golimumab for Patients with Moderate to Severe Crohn's Disease

Not recruiting
Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Colitis ulcerative

Not recruiting

Study on the Effects of Guselkumab and Golimumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:EstoniaEstonia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Multiple sclerosis

Not recruiting

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Colitis ulcerative

Not recruiting

Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis

Investigational
Countries:EstoniaEstonia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Cardiovascular disorder

Not recruiting

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Other cities in Estonia

The busiest research cities in the country

All 11 cities in Estonia

Clinical research in Pohja-Tallinna Linnaosa

What the registry says about research in the country

01 Neurological Disorders

Research focusing on evaluating treatments for multiple sclerosis, including long-term safety studies of medications like ocrelizumab and ofatumumab for patients with relapsing forms of MS.

  • Multiple Sclerosis (RMS)
  • Long-term Treatment Efficacy
  • Disease Modification
02 Gastrointestinal Conditions

Comprehensive studies investigating innovative therapies for inflammatory bowel diseases, including trials for both Crohn's Disease and Ulcerative Colitis using novel combination treatments.

  • Crohn's Disease
  • Ulcerative Colitis
  • Inflammatory Response
03 Cardiovascular Research

Studies evaluating new treatments for stroke prevention and management of atrial fibrillation, including trials of novel anticoagulants and therapeutic approaches.

  • Atrial Fibrillation
  • Stroke Prevention
  • Cardiovascular Disease
04 Urological Studies

Clinical investigations focusing on bladder cancer treatments and complicated urinary tract infections, evaluating new therapeutic approaches and medication combinations.

  • Bladder Cancer
  • Urinary Tract Infections
  • Novel Therapies
05 Nephrology Research

Innovative studies examining treatments for various kidney conditions, including IgA Nephropathy and focal segmental glomerulosclerosis, with focus on long-term outcomes.

  • Kidney Disease
  • Glomerular Disorders
  • Renal Function
Back to EstoniaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.